Orthocell Market cap - around $300m Share Price - $1.24
Orthocell submitted its application in December for FDA approval to distribute their Remplir product into the US. Remplir is used for repair of nerves. The remplir product is already approved and used in Australia, NZ & Singapore. If they get US approval, that will be a major step up in their potential revenue. The approval is expected in late March or early April, hence tipping now. Revenue is growing but the company is still operating at a loss. As with all FDA applications, there is a risk that they won't get the approval.
